METHODS FOR TREATMENT OF DOOSE SYNDROME, USING FENFLURAMINE Russian patent published in 2022 - IPC A61K31/135 A61P25/08 

FIELD: medicine; neurology; therapy.

SUBSTANCE: group of inventions relates to the field of medicine, namely to neurology and therapy; it is intended for the treatment of a patient with Doose syndrome. For the treatment of symptoms of Doose syndrome in the patient with Doose syndrome, a pharmaceutical composition is used, containing a pharmaceutically acceptable carrier and fenfluramine or its pharmaceutically acceptable salt in amount sufficient for the treatment, prevention, and/or relief of the specified symptoms of Doose syndrome in the patient. For stimulation of 5-HT-receptors in the patient with Doose syndrome, where the patient has a mutation in a gene selected from CHD2 (15q26), GABRG2 (5q34), SCN1A (2q24.3), SCN1B (19q13.12), SLC2A1 (1p34.2), and SLC6A1(3p25.3), a composition is used, containing an effective dose of fenfluramine or its pharmaceutically acceptable salt.

EFFECT: use of the group of inventions provides treatment, prevention, and/or relief of symptoms of Doose syndrome in a patient with Doose syndrome, as well as stimulation of 5-HT-receptors in a patient with Doose syndrome.

10 cl, 1 dwg, 8 tbl, 1 ex